Should Evidence-Based Proof of Drug Efficacy Be Extrapolated to a “Class of Agents”?
- 25 November 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (21) , 2608-2610
- https://doi.org/10.1161/01.cir.0000090572.51900.92
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)The Lancet, 2003
- Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attackThe Lancet, 2001
- The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular functionThe American Journal of Cardiology, 2001
- Are all angiotensin-converting enzyme inhibitors interchangeable?Journal of the American College of Cardiology, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Are drugs within a class interchangeable?The Lancet, 1999
- Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failureThe American Journal of Cardiology, 1998
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyNew England Journal of Medicine, 1996